---
title: Physiological Response to Salbutamol and Exercise
nct_id: NCT03902106
overall_status: UNKNOWN
phase: NA
sponsor: University of Copenhagen
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03902106.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03902106"
ct_last_update_post_date: 2020-11-03
last_seen_at: "2026-05-12T06:40:35.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Physiological Response to Salbutamol and Exercise

**NCT ID:** [NCT03902106](https://clinicaltrials.gov/study/NCT03902106)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** University of Copenhagen
- **Conditions:** Healthy
- **Start Date:** 2019-03-28
- **Completion Date:** 2021-06-30
- **CT.gov Last Update:** 2020-11-03

## Brief Summary

The scope of the study is to investigate the physiological response to salbutamol and exercise. A particular focus is on the metabolic response and amine metabolism.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy
* VO2max of \>55 ml/min/kg for men and \>50 ml/min/kg for women
* Body mass index (BMI) \< 26

Exclusion Criteria:

* Chronic use of beta2-agonist or allergy towards beta2-agonist
* Serious adverse effects to beta2-agonist
* Chronic disease deemed by the study responsible medical doctor to interfere with any part of the study
* Smoking
* Chronic use of prescription medicine deemed by the study responsible medical doctor to interfere with any part of the study
* Pregnancy (for women)
```

## Arms

- **beta2-agonist and exercise** (ACTIVE_COMPARATOR) — Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
- **placebo and exercise** (SHAM_COMPARATOR) — Subjects undergo exercise training with administration of sham placebo

## Interventions

- **salbutamol** (DRUG) — subjects ingest salbutamol
- **exercise** (OTHER) — subjects undergo 6 weeks of endurance training (3 times weekly)

## Primary Outcomes

- **Body composition** _(time frame: Baseline, 2 weeks, 4 weeks and 6 weeks)_ — Change in body composition (measured by dual energy x ray absorptiometry)
- **Maximal oxygen consumption (VO2max)** _(time frame: Baseline, 2 weeks, 4 weeks and 6 weeks)_ — Change in VO2max (measured during bike ergometer cycling to exhaustion)

## Secondary Outcomes

- **Salbutamol urine concentration** _(time frame: Before (baseline) as well as 0-1 hours, 1-2 hours, 2-4 hours, 4-8 hours, and 8-16 hours after administration)_

## Locations (1)

- August Krogh Building, Copenhagen, Denmark — _RECRUITING_

## Recent Field Changes (last 30 days)

- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.august krogh building|copenhagen||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03902106.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03902106*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*